Compartir
Título
dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
Autor(es)
Materia
Allergy
Asthma
Biomarkers
Immunological mechanisms
Immunomodulation
Biological treatment
Anti-IgE
Omalizumab
Immunoglobulin E (IgE)
Fecha de publicación
2017
Citación
Palomares, Ó., Sánchez-Ramón, S., Dávila, I., Prieto, L., Pérez de Llano, L., Lleonart, M., Domingo, C., et al. (2017). dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. International Journal of Molecular Sciences, 18(6), 1328. MDPI AG. http://dx.doi.org/10.3390/ijms18061328
Resumen
[EN] Asthma is an airway disease characterised by chronic inflammation with intermittent or
permanent symptoms including wheezing, shortness of breath, chest tightness, and cough, which
vary in terms of their occurrence, frequency, and intensity. The most common associated feature
in the airways of patients with asthma is airway inflammation. In recent decades, efforts have
been made to characterise the heterogeneous clinical nature of asthma. The interest in improving
the definitions of asthma phenotypes and endotypes is growing, although these classifications do
not always correlate with prognosis nor are always appropriate therapeutic approaches. Attempts
have been made to identify the most relevant molecular and cellular biomarkers underlying the
immunopathophysiological mechanisms of the disease. For almost 50 years, immunoglobulin E
(IgE) has been identified as a central factor in allergic asthma, due to its allergen-specific nature.
Many of the mechanisms of the inflammatory cascade underlying allergic asthma have already been
elucidated, and IgE has been shown to play a fundamental role in the triggering, development, and
chronicity of the inflammatory responses within the disease. Blocking IgE with monoclonal antibodies
such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic
asthma. A better understanding of the multiple contributions of IgE to the inflammatory continuum
of asthma could contribute to the development of novel therapeutic strategies for the disease.
URI
DOI
10.3390/ijms18061328
Versión del editor
Colecciones